

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### Long COVID review, Long COVID outcomes at 1 year, bivalent boosters, variants BQ1.1 and XBB.1

#### Peer reviewed journals featured

- A systematic review on COVID-19 convalescent plasma for immunocompromised patients [here](#)
- A narrative review on Long COVID [here](#) and associated commentary [here](#)
- Randomised controlled trials on:
  - Fluvoxamine in mild to moderate COVID-19 [here](#) and associated commentary [here](#)
  - COVID-19 booster vaccinations in healthy adults after priming with CoronaVac [here](#)
  - Bivalent Omicron BA.1–Adapted BNT162b2 booster in adults older than 55 years [here](#)
- Observational studies on:
  - Long COVID outcomes at one year after mild SARS-CoV-2 infection [here](#)
  - Safety monitoring of bivalent COVID-19 mRNA vaccine booster doses among children [here](#)
  - Outcomes among mechanically ventilated patients in SARS-CoV-2 and other aetiologies [here](#)
  - Risk of autoimmune diseases in patients with COVID-19 [here](#)
  - Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine [here](#)
  - Maternal and perinatal outcomes following pre-Delta, Delta, and Omicron variant infection among unvaccinated pregnant women [here](#)
  - Outcomes of extracorporeal membrane oxygenation for COVID-19 during successive SARS-CoV-2 variant outbreaks [here](#) and associated commentary [here](#)
  - Rituximab therapy in patients with rheumatic and musculoskeletal diseases [here](#) and associated commentary [here](#)
  - Real-world COVID-19 vaccine effectiveness against Omicron BA.2 in a SARS-CoV-2 infection-naive population [here](#)
  - Correlates of protection, thresholds of protection, and immuno-bridging in COVID-19 [here](#)
- Commentary on:
  - The COVID-19 pandemic in 2023: Far from over [here](#)
  - A new paradigm is needed to explain Long COVID [here](#)
  - Mass testing to end the COVID-19 public health threat [here](#)
  - What do we know about COVID-19 and children? [here](#)
  - Combating misinformation as a core function of public health [here](#)

## Letters and correspondence discussed

- Substantial neutralisation escape by SARS-CoV-2 Omicron variants BQ.1.1 and XBB.1 [here](#)
- Stability of hybrid versus vaccine immunity against BA.5 infection over 8 months [here](#)
- Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage [here](#)
- COVID-19 and other pandemics require a coherent response strategy [here](#)
- Antigenic mapping of Omicron variants BM.1.1.1, BQ.1.1, and XBB.1 [here](#)
- Protection against reinfection with the Omicron BA.2.75 subvariant [here](#)

## Pre-peer review articles featured

- Systematic reviews and meta-analyses on:
  - Global prevalence of COVID-19 reinfection [here](#)
  - Molnupiravir for adults with mild or moderate COVID-19 [here](#)
  - Mortality rates among patients with COVID-19 treated with convalescent plasma [here](#)
- A core outcome measurement set for research and clinical practice in Long COVID in adults [here](#)
- Effectiveness of early-treatment interventions on self-reported Long COVID [here](#)
- Enhanced transmissibility, infectivity and immune resistance of Omicron XBB.1.5 [here](#)
- Effectiveness of second booster compared to first booster and protection conferred by previous SARS CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France [here](#)
- Evasion of neutralising antibody response by Omicron XBB.1.5, CH.1.1 and CA.3.1 variants [here](#)
- Real-world data on molnupiravir in patients vaccinated against COVID-19 during Omicron [here](#)
- Plasma proteome of Long-COVID patients [here](#)

## Guidance and reports

- World Health Organization: Infection prevention and control in the context of COVID-19 [here](#) and BMJ visual summary of the WHO living guideline on COVID-19 drugs [here](#)
- UK Health Security Agency: SARS-CoV-2 variants of concern technical briefings [here](#)
- European Centre for Disease Prevention and Control: Threat assessment brief: Implications for the EU/EEA of the spread of the SARS-CoV-2 Omicron XBB.1.5 sub-lineage [here](#)

## News and blogs

- Swab the throat as well as the nose? The best way to test for SARS-CoV-2 [here](#)
- Florida's surgeon general "careless" in recommending against vaccination [here](#)
- China's COVID wave has probably peaked, model suggests [here](#)
- Will testing travellers from China keep new COVID variants out? [here](#)

[Click here](#) to subscribe to the daily evidence digest.

## Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).



Health

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.